Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/DNMT1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/DNMT1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/DNMT1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/DNMT1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/DNMT1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/DNMT1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001657014 | Oral cavity | LP | histone modification | 152/4623 | 463/18723 | 4.04e-05 | 5.90e-04 | 152 |
GO:003304415 | Oral cavity | LP | regulation of chromosome organization | 70/4623 | 187/18723 | 6.89e-05 | 9.22e-04 | 70 |
GO:200125217 | Oral cavity | LP | positive regulation of chromosome organization | 36/4623 | 82/18723 | 1.09e-04 | 1.31e-03 | 36 |
GO:000726515 | Oral cavity | LP | Ras protein signal transduction | 109/4623 | 337/18723 | 8.44e-04 | 7.36e-03 | 109 |
GO:003105613 | Oral cavity | LP | regulation of histone modification | 55/4623 | 152/18723 | 1.01e-03 | 8.48e-03 | 55 |
GO:00310581 | Oral cavity | LP | positive regulation of histone modification | 36/4623 | 92/18723 | 1.51e-03 | 1.18e-02 | 36 |
GO:00609685 | Oral cavity | LP | regulation of gene silencing | 32/4623 | 81/18723 | 2.24e-03 | 1.62e-02 | 32 |
GO:004002911 | Oral cavity | LP | regulation of gene expression, epigenetic | 39/4623 | 105/18723 | 3.00e-03 | 2.05e-02 | 39 |
GO:000110115 | Oral cavity | LP | response to acid chemical | 47/4623 | 135/18723 | 5.29e-03 | 3.23e-02 | 47 |
GO:004320013 | Oral cavity | LP | response to amino acid | 41/4623 | 116/18723 | 6.57e-03 | 3.85e-02 | 41 |
GO:001657023 | Oral cavity | EOLP | histone modification | 98/2218 | 463/18723 | 5.58e-09 | 2.96e-07 | 98 |
GO:003304422 | Oral cavity | EOLP | regulation of chromosome organization | 50/2218 | 187/18723 | 1.80e-08 | 7.94e-07 | 50 |
GO:000726522 | Oral cavity | EOLP | Ras protein signal transduction | 74/2218 | 337/18723 | 8.76e-08 | 3.09e-06 | 74 |
GO:000632515 | Oral cavity | EOLP | chromatin organization | 84/2218 | 409/18723 | 2.68e-07 | 8.16e-06 | 84 |
GO:003300212 | Oral cavity | EOLP | muscle cell proliferation | 56/2218 | 248/18723 | 1.25e-06 | 3.00e-05 | 56 |
GO:004269214 | Oral cavity | EOLP | muscle cell differentiation | 77/2218 | 384/18723 | 2.18e-06 | 4.91e-05 | 77 |
GO:004865915 | Oral cavity | EOLP | smooth muscle cell proliferation | 44/2218 | 184/18723 | 3.47e-06 | 7.48e-05 | 44 |
GO:003105622 | Oral cavity | EOLP | regulation of histone modification | 38/2218 | 152/18723 | 5.18e-06 | 1.05e-04 | 38 |
GO:004866015 | Oral cavity | EOLP | regulation of smooth muscle cell proliferation | 42/2218 | 180/18723 | 1.10e-05 | 1.93e-04 | 42 |
GO:001820521 | Oral cavity | EOLP | peptidyl-lysine modification | 72/2218 | 376/18723 | 2.38e-05 | 3.56e-04 | 72 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DNMT1 | SNV | Missense_Mutation | | c.461C>T | p.Pro154Leu | p.P154L | P26358 | protein_coding | tolerated_low_confidence(0.06) | benign(0) | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DNMT1 | SNV | Missense_Mutation | | c.2366N>T | p.Pro789Leu | p.P789L | P26358 | protein_coding | deleterious(0.03) | possibly_damaging(0.778) | TCGA-AR-A251-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
DNMT1 | SNV | Missense_Mutation | | c.4084G>C | p.Asp1362His | p.D1362H | P26358 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-BH-A0GY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyotxan | SD |
DNMT1 | SNV | Missense_Mutation | | c.3744G>T | p.Met1248Ile | p.M1248I | P26358 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-BH-A0GY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyotxan | SD |
DNMT1 | SNV | Missense_Mutation | | c.2401N>A | p.Asp801Asn | p.D801N | P26358 | protein_coding | tolerated(0.17) | benign(0.131) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DNMT1 | SNV | Missense_Mutation | novel | c.3280N>T | p.Gly1094Cys | p.G1094C | P26358 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-C8-A3M8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR |
DNMT1 | SNV | Missense_Mutation | novel | c.4388N>T | p.Ser1463Leu | p.S1463L | P26358 | protein_coding | deleterious(0.01) | possibly_damaging(0.662) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DNMT1 | SNV | Missense_Mutation | | c.2980N>C | p.Asp994His | p.D994H | P26358 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-E2-A1B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Adriamycin | SD |
DNMT1 | SNV | Missense_Mutation | rs749258509 | c.2623N>A | p.Asp875Asn | p.D875N | P26358 | protein_coding | tolerated(0.12) | benign(0.043) | TCGA-EW-A1PA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
DNMT1 | insertion | Nonsense_Mutation | novel | c.1100_1101insGTGGAGGGCTGGGCGCGGTGGCTCATGCCTGTAATCCTAGCACTTT | p.Lys368TrpfsTer11 | p.K368Wfs*11 | P26358 | protein_coding | | | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1786 | DNMT1 | DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | Guadecitabine | GUADECITABINE | |
1786 | DNMT1 | DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | DEMETHOXYCURCUMIN | DEMETHOXYCURCUMIN | 19112019 |
1786 | DNMT1 | DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | 5-FLUORODEOXYURIDINE | FLOXURIDINE | 15899874 |
1786 | DNMT1 | DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | IFOSFAMIDE | IFOSFAMIDE | |
1786 | DNMT1 | DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | TETRAHYDROCURCUMIN | TETRAHYDROCURCUMIN | 19112019 |
1786 | DNMT1 | DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | PMID27376512-Compound-PG-11048 | | |
1786 | DNMT1 | DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | DNDI1417346 | CHEMBL1490332 | |
1786 | DNMT1 | DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | S-110 | | |
1786 | DNMT1 | DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | ARSENIC TRIOXIDE | | 16613325 |
1786 | DNMT1 | DRUG RESISTANCE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | PMID27376512-Compound-CROs | | |